Table Graph
   

Vaxzevria (AstraZeneca Oxford - ChAdOx1 nCoV-19) - versus potential COVID-19 treatments - for COVID-19 prophylaxis (excluding children) pdf   xlsx method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 0.20 [0.02, 1.72]< 10%1 study (1/-)92.8 %NAnot evaluable crucial-
symptomatic Covid-19 0.29 [0.21, 0.39]< 165%2 studies (2/-)100.0 %lownot evaluable highimportant-
asymptomatic COVID case 0.33 [0.23, 0.48]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
infection (PCR positive symptomatic or not) 0.44 [0.33, 0.59]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
severe COVID-19 occurrence 0.49 [0.02, 14.54]< 10%1 study (1/-)65.9 %NAnot evaluable non important-
vaccine efficacy after dose 1 (and before dose 2) 0.24 [0.14, 0.41]< 10%1 study (1/-)100.0 %NAnot evaluable non important-

safety endpoints 00

serious adverse events 0.86 [0.64, 1.17]< 10%1 study (1/-)82.5 %NAnot evaluable important-
adverse events 1.37 [1.07, 1.74]< 160%4 studies (4/-)0.6 %NAnot evaluable non important-
ATE (Myocardial infarction or ischemic stroke) 0.39 [0.14, 1.06]< 10%2 studies (2/-)96.8 %NAnot evaluable non important-
Guillain-Barré syndrome 1.00 [0.03, 29.81]< 10%1 study (1/-)50.0 %NAnot evaluable non important-
intracranial hemorrhage 0.65 [0.12, 3.39]< 10%5 studies (5/-)69.6 %NAnot evaluable non important-
ischemic stroke 0.44 [0.11, 1.76]< 10%5 studies (5/-)87.8 %NAnot evaluable non important-
Myocardial infarction 0.57 [0.14, 2.31]< 10%5 studies (5/-)78.3 %NAnot evaluable non important-
pulmonary embolism 0.81 [0.15, 4.42]< 10%5 studies (5/-)59.7 %NAnot evaluable non important-
serious adverse events (SAE), any 0.87 [0.71, 1.06]< 10%3 studies (3/-)91.6 %NAnot evaluable non important-
venous thromboembolism 0.70 [0.07, 6.90]< 10%2 studies (2/-)62.0 %NAnot evaluable non important-

AE of interest endpoints 00

Bell's palsy 0.98 [0.23, 4.17]< 10%2 studies (2/-)51.1 %some concernnot evaluable moderatenon important-
immediate allergic reaction 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
multiple sclerosis 1.95 [0.07, 58.15]< 10%1 study (1/-)35.2 %NAnot evaluable non important-
myelitis 1.95 [0.18, 21.52]< 10%1 study (1/-)29.4 %NAnot evaluable non important-
Potential Immune Gastrointestinal disorders 0.33 [0.03, 3.13]< 10%1 study (1/-)83.3 %NAnot evaluable non important-
Potential Immune Musculoskeletal disorders 0.98 [0.06, 15.60]< 10%1 study (1/-)50.7 %NAnot evaluable non important-
Potential Immune Neuroinflammatory disorders 1.22 [0.33, 4.54]< 10%1 study (1/-)38.4 %NAnot evaluable non important-
Potential Immune Skin disorders 0.73 [0.16, 3.27]< 10%1 study (1/-)65.8 %NAnot evaluable non important-
Potential Immune Vasculitides 0.49 [0.02, 14.54]< 10%1 study (1/-)65.9 %NAnot evaluable non important-
Thromboembolic events 0.49 [0.15, 1.62]< 10%1 study (1/-)87.9 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons